Axon Enterprise’s (AXON) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Axon Enterprise (NASDAQ:AXON) in a research note released on Wednesday,Benzinga reports. They currently have a $600.00 target price on the biotechnology company’s stock.

Several other equities research analysts also recently weighed in on AXON. TD Cowen initiated coverage on Axon Enterprise in a report on Wednesday, January 8th. They set a “buy” rating and a $700.00 price target for the company. Robert W. Baird raised their target price on shares of Axon Enterprise from $600.00 to $800.00 and gave the stock an “outperform” rating in a research note on Friday, December 6th. The Goldman Sachs Group boosted their price target on shares of Axon Enterprise from $500.00 to $700.00 and gave the stock a “buy” rating in a research note on Monday, January 27th. JMP Securities restated an “outperform” rating on shares of Axon Enterprise in a research report on Tuesday, February 4th. Finally, Craig Hallum lowered Axon Enterprise from a “buy” rating to a “hold” rating and set a $625.00 price objective on the stock. in a report on Thursday, February 20th. Three analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $561.31.

Axon Enterprise Stock Up 15.3 %

Axon Enterprise stock opened at $572.40 on Wednesday. The stock has a 50 day moving average of $613.42 and a two-hundred day moving average of $522.06. Axon Enterprise has a twelve month low of $265.32 and a twelve month high of $715.99. The stock has a market capitalization of $43.65 billion, a price-to-earnings ratio of 147.91, a PEG ratio of 5.17 and a beta of 1.05. The company has a current ratio of 2.96, a quick ratio of 2.63 and a debt-to-equity ratio of 0.32.

Insider Buying and Selling

In related news, insider Jeffrey C. Kunins sold 2,304 shares of the stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $654.79, for a total value of $1,508,636.16. Following the sale, the insider now directly owns 128,542 shares of the company’s stock, valued at approximately $84,168,016.18. This represents a 1.76 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Julie A. Cullivan sold 1,261 shares of Axon Enterprise stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $682.06, for a total transaction of $860,077.66. Following the transaction, the director now owns 2,392 shares of the company’s stock, valued at approximately $1,631,487.52. The trade was a 34.52 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 8,711 shares of company stock valued at $5,631,561. 5.70% of the stock is owned by insiders.

Institutional Trading of Axon Enterprise

Several large investors have recently modified their holdings of AXON. Allworth Financial LP lifted its stake in Axon Enterprise by 7.1% in the 3rd quarter. Allworth Financial LP now owns 1,006 shares of the biotechnology company’s stock valued at $402,000 after buying an additional 67 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Axon Enterprise by 23.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,329 shares of the biotechnology company’s stock worth $2,502,000 after buying an additional 1,196 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Axon Enterprise by 35.7% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 12,422 shares of the biotechnology company’s stock worth $4,964,000 after acquiring an additional 3,269 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its position in shares of Axon Enterprise by 1.6% in the third quarter. DekaBank Deutsche Girozentrale now owns 22,812 shares of the biotechnology company’s stock valued at $8,948,000 after acquiring an additional 362 shares in the last quarter. Finally, Nisa Investment Advisors LLC boosted its stake in shares of Axon Enterprise by 6.3% during the third quarter. Nisa Investment Advisors LLC now owns 3,784 shares of the biotechnology company’s stock valued at $1,512,000 after acquiring an additional 225 shares during the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.